Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
about
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human.Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic ClearanceA nucleotide-gated molecular pore selects sulfotransferase substrates.Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1)A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.The role of drug metabolizing enzymes in clearance.Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans.Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge.Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition.Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor.Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery.Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.Protein Abundance of Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation.The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans.Phenolic sulfates as new and highly abundant metabolites in human plasma after ingestion of a mixed berry fruit purée.Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.
P2860
Q30585329-F8239FF5-20B3-4BBE-95CC-3CC8D23344CCQ30661362-F07EC03F-6574-4CF2-90BC-FFB1EA7D7E58Q33588394-E1D2D138-1748-4864-9B19-4D23C961D567Q36250026-FBBB5065-93F2-403D-B999-CF3F93E2C8B5Q36595916-23D81C2C-8658-4839-9805-C61EC781C2D0Q37062619-B60766D6-0FF3-40AE-9B79-A0A39F6092C3Q37599474-5DAC645B-8B8C-4A40-9721-77C3D924A824Q37600381-87B1B1E4-6025-4C2F-92B3-7F5C7824C941Q38017309-CF565152-293E-4212-A900-96A891AD3906Q38176051-A983E37C-F90B-4034-99A8-8166AAF8A84AQ38799423-B2F01D1E-6A6D-44D7-ADD5-57B60A8B2B85Q38800092-312C1C61-C178-49E4-AA13-2D03C46C60D6Q38853020-3581AD5E-E0B9-4273-8D5C-1D38E715461EQ38951944-391BA865-D76B-4837-9B46-0014FFCEB309Q39336170-46496E7D-7649-4508-A36B-7C3F542976EDQ39952608-7598DDB0-DCA9-489D-BB98-914B3F10EDADQ45273697-25895816-35FA-4A22-9071-451EBEE151AAQ45851514-995507B1-6F72-40EB-951B-BA19DD85F564Q46715656-1A0203B3-BCE9-4BBF-A055-C832B9E6168AQ47330563-C108E192-18E4-42B4-9088-CDB8E33E43DDQ50146193-EA3F422D-0C4F-43B3-AC8B-04F29CFF2416Q50770722-0A1308E0-B92A-4135-9D51-3EDC52441790Q50871327-3F452E84-B536-47AA-AA7F-2371CAF39C9DQ51072946-A00BE931-C05A-478A-8003-7F15A1A24493Q52838045-532873F5-CC6F-4E6E-A148-0C2722C3D273Q55058919-EC810C25-34FB-4BDE-98B0-533868D87AAC
P2860
Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prediction of human drug clear ...... microsomal and cytosolic data.
@ast
Prediction of human drug clear ...... microsomal and cytosolic data.
@en
type
label
Prediction of human drug clear ...... microsomal and cytosolic data.
@ast
Prediction of human drug clear ...... microsomal and cytosolic data.
@en
prefLabel
Prediction of human drug clear ...... microsomal and cytosolic data.
@ast
Prediction of human drug clear ...... microsomal and cytosolic data.
@en
P356
P1476
Prediction of human drug clear ...... microsomal and cytosolic data.
@en
P2093
Helen E Cubitt
J Brian Houston
P304
P356
10.1124/DMD.110.036566
P577
2011-02-08T00:00:00Z